Investors sentiment decreased to 0.98 in 2017 Q2. Its down 0.13, from 1.11 in 2017Q1. It worsened, as 24 investors sold Sage Therapeutics, Inc. shares while 61 reduced holdings.
A number of hedge funds have recently made changes to their positions in the stock. Dubuque National Bank & Trust Trust holds 2,100 shares. As of this writing, Sage Therapeutics, Inc.'s RSI stands at 87.46.
Sage Therapeutics (NASDAQ:SAGE)'s stock had its "overweight" rating reiterated by stock analysts at J P Morgan Chase & Co in a research report issued on Friday. Airain Ltd holds 0.06% or 17,281 shares in its portfolio. X Management Ltd Liability stated it has 210 shares. New Leaf Venture Prns Limited Liability Corp owns 3.8% invested in Sage Therapeutics, Inc. Sphera Funds owns 5,000 shares or 0.07% of their USA portfolio. Comml Bank Of America Corp De holds 0% of its portfolio in Sage Therapeutics, Inc.
Investors are sharpening their focus on shares of Spire Inc. Rhumbline Advisers accumulated 41,138 shares. Ameriprise Fincl Inc holds 59,336 shares or 0% of its portfolio. The Illinois-based Ubs Asset Mngmt Americas has invested 0% in Sage Therapeutics, Inc.
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. Palo Alto Invsts Ltd Liability Corporation holds 3.84% or 1.03 million shares in its portfolio. Victory Capital Mgmt accumulated 445,485 shares or 0.08% of the stock. (NASDAQ:SAGE). Wells Fargo And Mn stated it has 0% in Sage Therapeutics, Inc. (NYSE:SR). According to First Call, the consensus price target for the company is $79.89. The 6 months bullish chart indicates low risk for the $6.60B company. This technical setup was reported by Barchart.com. If the $165.55 price target is reached, the company will be worth $197.97M more. It has outperformed by 99.75% the S&P500. Sage Therapeutics has a one year low of $44.55 and a one year high of $100.50.
SAGE has been the subject of several other research reports. They expect $-2.00 earnings per share, down 33.33% or $0.50 from last year's $-1.5 per share. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($1.98) by $0.01. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.08 average brokerage recommendation. Therefore 88% are positive.
I believe Zuma is guilty of rape, Says S.African VP
The ANC's new leader will be its presidential candidate in the 2019 elections, which will bring an end to Zuma's second term. In 2005 Kuzwayo‚ also known as Khwezi‚ accused Zuma of raping her at his home in Forest Town‚ Johannesburg.
Praising the depression drug's safety profile, the analyst elaborates: "Safety clean, highly encouraging SAGE-217 showed a clean safety profile with adverse events consistent with prior studies, including headache, dizziness, nausea, and somnolence". The stock has "Buy" rating by Canaccord Genuity on Tuesday, September 12. Cowen & Co maintained the stock with "Buy" rating in Thursday, November 9 report. BMO Capital Markets' price target points to a potential upside of 29.90% from the company's current price. Raymond James upgraded Sage Therapeutics, Inc. Needham maintained the stock with "Buy" rating in Tuesday, June 13 report. The stock has "Neutral" rating by H.C. Wainwright on Wednesday, February 22. The firm has "Buy" rating by Cowen & Co given on Tuesday, September 5. On Thursday, December 7 the stock rating was maintained by Leerink Swann with "Buy". Canaccord Genuity maintained Sage Therapeutics, Inc. Also Cnbc.com published the news titled: "Sage Therapeutics shares soar after postpartum depression drug meets main goal" on November 09, 2017.
"It's hard to understate how meaningful these data are in the backdrop of the very significant unmet medical need in depression: even if the SAGE data on a placebo-adjusted basis weren't differentiated via cross-trial comparisons, we still think '217 would be an important drug as it offers a new mechanism (extra-synaptic GABA-modulation) in an area where the vast majority of options generally modulate the same pathways (serotonin, dopamine, norepinephrine)", said Leerink.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's market cap is $2.58 billion.
Analysts said Thursday's data backs the drug's mechanism, which is different from other treatments approved by the FDA in the last two decades. It now has negative earnings.
Sage Therapeutics (NASDAQ:SAGE) is up 52% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.